Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBITDA (2016 - 2025)

Historic EBITDA for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' EBITDA rose 2020.78% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.6 million, marking a year-over-year increase of 5237.49%. This contributed to the annual value of $163.9 million for FY2024, which is 12960.64% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its EBITDA stood at $52.8 million for Q3 2025, which was up 2020.78% from $52.2 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year EBITDA high stood at $56.7 million for Q1 2025, and its period low was -$30.8 million during Q3 2023.
  • For the 5-year period, Catalyst Pharmaceuticals' EBITDA averaged around $27.3 million, with its median value being $25.5 million (2022).
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 23429.94% in 2023, then surged by 24262.87% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBITDA (Quarter) stood at $9.2 million in 2021, then skyrocketed by 176.05% to $25.5 million in 2022, then skyrocketed by 36.84% to $34.8 million in 2023, then surged by 60.72% to $56.0 million in 2024, then decreased by 5.8% to $52.8 million in 2025.
  • Its last three reported values are $52.8 million in Q3 2025, $52.2 million for Q2 2025, and $56.7 million during Q1 2025.